Navigation Links
Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
Date:5/31/2010

SAN FRANCISCO, CA/ATLANTA, GA, June 1, 2010 - Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

Evaluating a combined total of 556 (randomized) and 536 (treated) men with primary PE in the United States, Canada and Europe over a three-month period, with more than 23,000 exposures to PSD502 recorded, the data demonstrated that men who were treated with PSD502 five minutes before intercourse by applying PSD502 via a topical metered dose spray had a time to ejaculation 5.5 times longer than those who used a placebo spray with the actual average measurement in minutes for drug and placebo.

A co-primary endpoint also looked at ejaculatory control and satisfaction. Point differences of 6.1 and 5.3 were observed between the PSD502 group and placebo in ejaculatory control and satisfaction domains, respectively (p<0.0001 for all).

"Combined results from the PSD502 pivotal studies are very exciting and this is a significant milestone," said Ira D. Sharlip, MD, clinical trial investigator and clinical professor of urology at the University of California, San Francisco.

The exact incidence of PE is not known, as a widely accepted definition of PE has only recently become available. Depending on the definition used, ranges from 5% to more than 30% incidence of PE or ejaculatory control issues have been reported in the literature. For example, according to a large national study, approximately 30% of men suffer from ejaculatory control issues, including climaxing too early, while data from the National Health and Social Life Survey (NHSLS) states the prevalence as 21% in men ages 18 to 59 in the Un
'/>"/>

Contact: Dave Schemelia
dschemelia@healthstarpr.com
609-468-9325
HealthStar PR
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
2. Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
3. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
4. BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment
5. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
6. Steroids May Be Overrated in Treatment of COPD
7. Experimental stem cell treatment arrests acute lung injury in mice, study shows
8. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
9. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
10. New York City Surgeon Develops All-Natural Treatment for Wrinkles and Scars
11. Novelty lures rats from cocaine-paired settings, hinting at new treatments for recovering addicts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... The University of California, Davis and ... initiative at UC Davis School of Medicine dedicated ... to advancing Latino health. , The program, called ... to Be Physicians, (“Prep Médico” for short) is ... and internship opportunities, a residential program, intensive language ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... in specialized insurance programs, announces the expansion of coverage ... ESIP is a leading provider of industry-tailored insurance and ... “At McNeil & Company, we are dedicated to providing ... coverage to meet their many evolving needs. We are ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 TROY Healthcare ... Cerner North Atlantic Regional User Group (RUG) Conference in ... Cerner North Atlantic Regional User Group provides an opportunity ... and explore the exhibitor gallery. , In addition to ... at the Cerner North Atlantic RUG Conference. Attendees can ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
(Date:5/4/2015)... Now in its seventh year, the ... have made outstanding contributions to the company, to their ... acute and post-acute care settings. The five award categories ... the Year, Advanced Practice Clinician of the Year, Newcomer ... Year. Recipients are selected by IPC’s senior management team. ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... Registration, Evaluation and Authorization of Chemicals, has shifted the burden ... ,The chemical companies would be bound by law to ... business. ,This law aims to make chemicals used ... users and the environs. ,The European Parliament has ...
... of three doctors on an indefinite hunger strike here ... deteriorated Sunday.// ,The three are under observation ... of the All India Institute of Medical Sciences (AIIMS) ... a bill favouring quotas. ,"Their condition has ...
... the National Surgical Adjuvant Breast and Bowel Project ... Antonio Breast Cancer Symposium, showed that// postmenopausal women ... after five years of tamoxifen were 56% less ... than those who received placebo (P=0.004). ...
... slow the loss of central vision has shown promise ... which involves the same central// light-sensitive area of retina, ... ,Encouraged by the effect of ranibuzumab in people ... into the eyes of 10 people losing their sight ...
... certain types of inhaled particles in occupational settings and ... lung cancer risk. The December// Journal of Occupational and ... Occupational and Environmental Medicine (ACOEM), is a special issue ... remarkable consistency exists among many types of studies for ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Drug Treatment Slows Macular Vision Loss in Diabetics 2Health News:Inhaled Particles Increases the Risk of Lung Cancer 2Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2
(Date:5/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... first quarter ended March 31, 2015 and provided a ... equity offering in February, which raised net proceeds ... strong financial position to advance our lead pipeline ...
(Date:5/4/2015)... 4, 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... for the first quarter ending March 31, 2015. ... In our first full quarter since the commercial launch, we ... treatment for nonsense mutation Duchene Muscular Dystrophy. We now have ... treatment since our last earnings call," stated Stuart W. ...
(Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 9DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... 6, 2012  Genomic Health, Inc. (Nasdaq: GHDX ) ... the goal of improving the quality of diagnosis, communication and ... common and rare genetic conditions.   The subsidiary is expected to ... commercial service in 2013.  The new venture will be led ...
... (LSE: SN, NYSE: SNN ), the global ... subsidiary, Smith & Nephew, Inc., have reached settlements with ... Department of Justice (DOJ) in connection with their Foreign ... Smith & Nephew has committed to pay $22,226,799 in ...
Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4Smith & Nephew Reaches Settlement With US Government 2Smith & Nephew Reaches Settlement With US Government 3
Exo-Deluxe Overhead Traction for hospital or home care. Twice the clearance of other units between the patient and supporting wall. 2" nylon pulleys with polypropylene cord, head halter, spreader bar...
Wonderflex™ is a lined soft durometer silicone gel sheet. It is ideal for cushioning orthotic/prosthetic devices and offers protection from shock and sheer forces. Wonderflex can also be lamina...
Designed to provide relief from chronic or acute back pain by unloading pressure off the lumbar discs and shifting pressure to the abdominal region...
Effectively stabilize and relax your back with the LumboTrain back support....
Medicine Products: